Safety boundary: This page cannot diagnose BPH or prostate cancer, interpret an individual result or recommend delaying care. Urinary retention, heavy bleeding, severe pain, fever with urinary symptoms or rapid deterioration need prompt medical attention.
Direct answer
The useful next step is not to label one result “good” or “bad.” Verify the result and testing conditions, connect it to prior values, medicines and clinical risk, then ask which additional information would materially change the decision.
Decision table
| Factor | What it tells you | What still needs interpretation |
|---|
| What is measured | Total PSA includes circulating PSA that is free and PSA bound to proteins. | Free PSA is the unbound component measured by the assay. |
|---|
| Common calculation | Percent-free PSA is free PSA divided by total PSA, multiplied by 100. | The calculation is only meaningful when both values are compatible and clinically applicable. |
|---|
| Decision role | Total PSA is the starting measurement in many screening or diagnostic pathways. | Percent-free PSA may be one additional risk-refinement input in selected situations. |
|---|
| What it cannot do | A total value cannot identify the cause by itself. | A percent-free result cannot confirm cancer, rule it out or choose a biopsy by itself. |
|---|
| Assay and timing | Laboratory method, dates and clinical conditions should be checked. | Do not combine values from incompatible tests or different clinical episodes without guidance. |
|---|
| Next-step context | History, examination, prior tests and preferences remain relevant. | MRI, another biomarker, repeat PSA or biopsy may be discussed depending on overall risk—not the ratio alone. |
|---|
Calculate carefully, interpret cautiously
The arithmetic is straightforward: percent-free PSA = free PSA ÷ total PSA × 100. The clinical interpretation is not straightforward. A percentage does not carry a universal verdict because the intended use, total PSA range, assay, prior testing and patient risk context matter.
This page intentionally does not publish a red-yellow-green percentage table. Such tables strip away the population, follow-up and decision context behind their thresholds. If a clinician ordered free PSA, ask what question they expected it to answer and what action would—or would not—follow from the result.
Consultation checklist
- Confirm free and total PSA were measured from the same clinical episode.
- Ask which laboratory assay was used.
- Ask why percent-free PSA was selected instead of or alongside another test.
- Review family history, prior biopsy, MRI and examination findings.
- Request absolute risk language rather than “good” or “bad.”
- Ask what result would change the proposed next step.
Shortcuts to reject
- Treating percent-free PSA as a cancer test.
- Using a percentage without the total PSA value.
- Applying a web cutoff to every age or risk group.
- Assuming a reassuring ratio means no follow-up is needed.
How to use evidence without overreading it
Guidelines describe how groups of patients may be evaluated; prescribing information explains known drug effects; studies report outcomes in defined populations. None can supply the missing details of an individual medical history. Check the evidence date, population, exclusions, assay or imaging method, and the decision the source was designed to support.
UriSmooth does not diagnose prostate disease and is not presented as an alternative to repeat testing, imaging, biopsy or treatment. The commercial owner of this site benefits from supplement sales, so this testing cluster deliberately uses clinician-discussion actions rather than a product CTA.
Sources and review status
Sources checked September 22, 2026. These drafts remain outside the XML sitemap until a qualified reviewer verifies current guidance, labels, claims and patient-facing balance. Source organizations do not endorse UriSmooth.
Frequently asked questions
1. What should I know about the difference between free and total PSA?
The difference between free and total PSA may refine selected PSA discussions, but the ratio is not diagnostic. Confirm compatible free and total values, assay context and the clinical question before attaching meaning to a percentage.
2. What should I know about the percent-free formula?
The percent-free formula may refine selected PSA discussions, but the ratio is not diagnostic. Confirm compatible free and total values, assay context and the clinical question before attaching meaning to a percentage.
3. What should I know about a low percent-free result?
A low percent-free result may refine selected PSA discussions, but the ratio is not diagnostic. Confirm compatible free and total values, assay context and the clinical question before attaching meaning to a percentage.
4. What should I know about a high percent-free result?
A high percent-free result may refine selected PSA discussions, but the ratio is not diagnostic. Confirm compatible free and total values, assay context and the clinical question before attaching meaning to a percentage.
5. What should I know about test accuracy?
Test accuracy belongs in a defined clinical decision, not a keyword shortcut. Ask what it measures, what it misses, whether it applies to your situation and exactly how it would change the next step.
6. What should I know about laboratory methods?
Laboratory methods can affect PSA context or measurement. Record timing honestly and ask whether the result should be confirmed after the relevant condition resolves; do not self-treat merely to change a test.
7. What should I know about repeat testing?
Repeat testing depends on why the test was ordered and whether temporary influences or concerning findings are present. A clinician should set the interval; repeating a newly elevated result can be appropriate, but delay is not automatically safe in every case.
8. What should I know about PSA density?
PSA density links PSA to measured prostate volume. Check the imaging method and dates, then treat the calculation as one risk input—not proof of BPH, cancer or the need for a procedure.
9. What should I know about PSA velocity?
PSA velocity needs dated values collected in a comparable clinical context. A trend can support risk assessment, but it cannot explain the cause or act as the sole trigger for imaging or biopsy.
10. What should I know about MRI after PSA?
MRI after PSA can add anatomical or risk information, but it does not make every diagnosis. Ask what result would change the plan, whether the image is current and how a negative or uncertain finding will be handled.
11. What should I know about biopsy decisions?
Biopsy decisions is a tissue-sampling decision, not an automatic consequence of one PSA value. For free psa vs total psa: what the ratio can—and cannot—add, ask how repeat testing, overall risk, MRI or biomarkers change the expected benefit and harms of biopsy.
12. What should I know about risk calculators?
Risk calculators can look precise while hiding uncertainty. Use the original report, prior values, medicines, prostate findings and personal risk context; this page does not turn a number into a diagnosis.
Related decisions
Return to the PSA and diagnostic-test hub, review possible next-step discussions after an elevated PSA, or prepare for tests before BPH treatment.